Overall verdict
Neutral
6.3/10
1-year performance
+46.50%
Score breakdown
Up 46.5% over 1 year, 29% of the 52-week range.
6 analysts.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers ; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Fred Aslan
Founded
2019
Employees
104
Revenue / employee
0 USD
Next earnings
November 12, 2026 (estimated)
Institutional holders
- RA CAPITAL MANAGEMENT, L.P.36.73%
- VIKING GLOBAL INVESTORS LP5.33%
- Blackstone Inc.4.92%
- 5AM Venture Management, LLC4.81%
- Venrock Adviser, LLC4.18%
- FRANKLIN RESOURCES INC4.09%
- Caligan Partners LP3.55%
- VANGUARD CAPITAL MANAGEMENT LLC2.01%
- SAMSARA BIOCAPITAL, LLC1.95%
- Other institutions15.02%
- Rest of the register17.42%
73 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
14.53 USD
52-week low
2.96 USD
1-year performance
46.50%
Rising
Year-to-date performance
45.15%
Rising
Drawdown
-56.74%
Major drawdown
Position in the 52-week range
29% of range
ROIC -35.4%, ROE -36.6%.
Net margin
—
Sector -14.60%|S&P 13.15%
Gross margin
—
Return on equity (ROE)
-36.58%
Negative
Sector -15.76%|S&P 16.61%
Return on invested capital (ROIC)
-35.43%
Negative
Free cash flow margin (FCF)
—
Revenue to net income
Growth
0.0/10Revenue down 100.0% over 1 year.
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
-100.00%
Declining
Revenue growth (3y)
-100.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
3.6/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 30.7x|S&P 24.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
0.3x
Cheap
Sector 22.8x|S&P 15.2x
PEG
—
Sector 0.35|S&P 0.90
Market cap
307M USD
Financial strength
10.0/10Cash covers 3547.5% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-97.71%
Net cash
Cash
349M USD
Cash / market cap
113.71%
Very solid
Cash / total debt
3547.51%
Net cash
Net debt
-340M USD
Equity
348M USD
Closed daily candles, 2 years
Last close on October 21, 2026: 6.49 USD
- MM206.71
- MM509.01
- MM2008.01
- RSI 1437.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.63%
200-day average slope, 3 months
+27.96%
50-day average slope, 1 month
-14.44%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
4.23 % per day
Volatility change
-24.28%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -2.59 (6) | -2.51 (5) | 0 (6) | — | -107 (6) |
| 2027 | -2.71 (6) | -2.61 (5) | 0 (6) | — | -135 (6) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 2, 2026.
Same sub-industry: 411 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARTV | 6.3 | N/A | 307M USD | Not meaningful (loss) | — | -100.0 % | -35.4 % | — | -25.0 % | 46.5 % | ||
| 2 | VRTX | 6.2 | 5.8 | 133Md USD | 30.5x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 25.6 % | ||
| 3 | ABBV | 6.0 | 5.1 | 503Md USD | 80.5x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.6 % | 22.7 % | ||
| 4 | AMGN | 6.0 | 5.9 | 237Md USD | 27.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.3 % | 44.9 % | ||
| 5 | REGN | 5.7 | 5.6 | 82.9Md USD | 19.9x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.5 % | 40.2 % | ||
| 6 | CSL | 4.7 | 3.9 | 66.1Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | -11.0 % | ||
| 7 | GILD | 4.4 | 3.0 | 190Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.8 % | 24.6 % | ||
| 8 | NTRA | 4.3 | 3.0 | 59.6Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 119.9 % | ||
| 9 | MRNA | 2.8 | 1.3 | 98.1Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.3 % | 802.1 % |
